化疗与放疗在局限性骨外骨肉瘤中的作用
这项回顾性多中心研究纳入370例1971至2016年接受根治性手术的局限性骨外骨肉瘤成人患者,评估化疗和放疗与复发及生存的关联。5年生存率为56%(95%CI 51%-62%),47%患者出现复发;放疗与局部复发降低显著相关(HR 0.46,95%CI 0.26-0.80,p=0.01),化疗未降低系统复发风险,两者均未改善生存。
要点
- 局限性骨外骨肉瘤根治性手术后5年生存率为56%(95%CI 51%-62%)。
- 辅助放疗与局部复发风险降低显著相关(HR 0.46,95%CI 0.26-0.80,p=0.01)。
- 化疗未降低系统复发风险,化疗或放疗均未与生存改善相关。
核心结论
- 放疗显著降低局部复发,但化疗未降低系统复发风险,且化疗、放疗或两者联合均未改善局限性骨外骨肉瘤患者的生存。
- 结果不支持使用化疗,但辅助放疗对可局部切除的骨外骨肉瘤患者显示获益。
研究设计与样本
- 国际25家肉瘤中心的回顾性研究,纳入1971至2016年接受治疗的370例≥18岁局限性骨外骨肉瘤患者。
- 采用Kaplan-Meier生存分析、Cox比例风险回归和累积发生率竞争风险分析。
主要发现
- 370例患者中深部肿瘤294例(80%),仅手术122例,手术加化疗96例(26%),加放疗70例(19%),两者均加82例(22%)。
- 5年生存率为56%(95%CI 51%-62%)。
- 173例(47%)出现复发:局部9%(35/370)、远处28%(102/370)、两者兼有10%(36/370)。
- 以死亡为竞争事件,接受化疗、放疗、两者或均未接受的患者间局部或系统复发的累积发生率无显著差异(局部p=0.50,系统p=0.69)。
- 多因素Cox分析显示放疗与局部复发降低显著相关(HR 0.46,95%CI 0.26-0.80,p=0.01)。
临床怎么用
- 对于可局部切除的局限性骨外骨肉瘤,辅助放疗可考虑用于降低局部复发风险。
- 结果不支持对该人群常规使用辅助化疗以改善系统复发或生存。
局限性
- 回顾性研究设计,存在选择偏倚和混杂因素可能。
- 样本来自25个中心跨越1971至2016年,治疗策略和影像/病理评估可能随时间变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of chemotherapy (CT) and radiotherapy (RT) for management of extraskeletal osteosarcoma (ESOS) remains controversial. We examined disease outcomes for ESOS patients and investigated the association between CT/RT with recurrence and survival. PATIENTS AND METHODS: Retrospective review at 25 international sarcoma centers identified patients ≥18 years old treated for ESOS from 1971 to 2016. Patient/tumour characteristics, treatment, local/systemic recurrence, and survival data were collected. Kaplan-Meier survival and Cox proportional-hazards regression and cumulative incidence competing risks analysis were performed. RESULTS: 370 patients with localized ESOS treated definitively with surgery presented with mainly deep tumours (n = 294, 80%). 122 patients underwent surgical resection alone, 96 (26%) also received CT, 70 (19%) RT and 82 (22%) both adjuvants. Five-year survival for patients with localized ESOS was 56% (95% CI 51%-62%). Almost half of patients (n = 173, 47%) developed recurrence: local 9% (35/370), distant 28% (102/370) or both 10% (36/370). Considering death as a competing event, there was no significant difference in cumulative incidence of local or systemic recurrence between patients who received CT, RT, both or neither (local p = 0.50, systemic p = 0.69). Multiple regression Cox analysis showed a significant association between RT and decreased local recurrence (HR 0.46 [95% CI 0.26-0.80], p = 0.01). CONCLUSION: Although the use of RT significantly decreased local recurrences, CT did not decrease the risk of systemic recurrence, and neither CT, nor RT nor both were associated with improved survival in patients with localized ESOS. Our results do not support the use of CT; however, adjuvant RT demonstrates benefit in patients with locally resectable ESOS.
引用
- Heng M, Gupta A, Chung PW, et al. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma. Eur J Cancer. 2019. PMID: 31806415. doi:10.1016/j.ejca.2019.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。